These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
915 related articles for article (PubMed ID: 34047765)
1. Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer. Massarweh A; Eliakim-Raz N; Stemmer A; Levy-Barda A; Yust-Katz S; Zer A; Benouaich-Amiel A; Ben-Zvi H; Moskovits N; Brenner B; Bishara J; Yahav D; Tadmor B; Zaks T; Stemmer SM JAMA Oncol; 2021 Aug; 7(8):1133-1140. PubMed ID: 34047765 [TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis. Yau K; Abe KT; Naimark D; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Mullin SI; Shadowitz E; Gonzalez A; Sukovic T; Garnham-Takaoka J; de Launay KQ; Takaoka A; Straus SE; McGeer AJ; Chan CT; Colwill K; Gingras AC; Hladunewich MA JAMA Netw Open; 2021 Sep; 4(9):e2123622. PubMed ID: 34473256 [TBL] [Abstract][Full Text] [Related]
4. COVID-19 vaccines in adult cancer patients with solid tumours undergoing active treatment: Seropositivity and safety. A prospective observational study in Italy. Cavanna L; Citterio C; Biasini C; Madaro S; Bacchetta N; Lis A; Cremona G; Muroni M; Bernuzzi P; Lo Cascio G; Schiavo R; Mutti M; Tassi M; Mariano M; Trubini S; Bandieramonte G; Maestri R; Mordenti P; Marazzi E; Vallisa D Eur J Cancer; 2021 Nov; 157():441-449. PubMed ID: 34601285 [TBL] [Abstract][Full Text] [Related]
5. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study. Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185 [TBL] [Abstract][Full Text] [Related]
6. The dynamics of quantitative SARS-CoV-2 antispike IgG response to BNT162b2 vaccination. Kaneko S; Kurosaki M; Sugiyama T; Takahashi Y; Yamaguchi Y; Nagasawa M; Izumi N J Med Virol; 2021 Dec; 93(12):6813-6817. PubMed ID: 34314037 [TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Monin L; Laing AG; Muñoz-Ruiz M; McKenzie DR; Del Molino Del Barrio I; Alaguthurai T; Domingo-Vila C; Hayday TS; Graham C; Seow J; Abdul-Jawad S; Kamdar S; Harvey-Jones E; Graham R; Cooper J; Khan M; Vidler J; Kakkassery H; Sinha S; Davis R; Dupont L; Francos Quijorna I; O'Brien-Gore C; Lee PL; Eum J; Conde Poole M; Joseph M; Davies D; Wu Y; Swampillai A; North BV; Montes A; Harries M; Rigg A; Spicer J; Malim MH; Fields P; Patten P; Di Rosa F; Papa S; Tree T; Doores KJ; Hayday AC; Irshad S Lancet Oncol; 2021 Jun; 22(6):765-778. PubMed ID: 33930323 [TBL] [Abstract][Full Text] [Related]
8. Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel. Spitzer A; Angel Y; Marudi O; Zeltser D; Saiag E; Goldshmidt H; Goldiner I; Stark M; Halutz O; Gamzu R; Slobodkin M; Amrami N; Feigin E; Elbaz M; Furman M; Bronstein Y; Chikly A; Eshkol A; Furer V; Mayer T; Meijer S; Melloul A; Mizrahi M; Yakubovsky M; Rosenberg D; Safir A; Spitzer L; Taleb E; Elkayam O; Silberman A; Eviatar T; Elalouf O; Levinson T; Pozyuchenko K; Itzhaki-Alfia A; Sprecher E; Ben-Ami R; Henig O JAMA; 2022 Jan; 327(4):341-349. PubMed ID: 35006256 [TBL] [Abstract][Full Text] [Related]
9. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines. Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093 [TBL] [Abstract][Full Text] [Related]
10. Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months. Hsu CM; Weiner DE; Manley HJ; Aweh GN; Ladik V; Frament J; Miskulin D; Argyropoulos C; Abreo K; Chin A; Gladish R; Salman L; Johnson D; Lacson EK Clin J Am Soc Nephrol; 2022 Mar; 17(3):403-413. PubMed ID: 35144972 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of BNT162b2 vaccination in patients with solid cancer receiving anticancer therapy - a single centre prospective study. Shmueli ES; Itay A; Margalit O; Berger R; Halperin S; Jurkowicz M; Levin EG; Levy I; Olmer L; Regev-Yochay G; Lustig Y; Rahav G Eur J Cancer; 2021 Nov; 157():124-131. PubMed ID: 34508994 [TBL] [Abstract][Full Text] [Related]